恩格列净对急性心力衰竭减充血的影响:EMPULSE试验
EMPULSE试验将530例急性心衰住院患者随机分配至恩格列净10mg每日一次或安慰剂治疗90天,评估减充血相关终点。结果显示恩格列净组在第15、30、90天的体重减轻、利尿剂调整后体重减轻、NT-proBNP变化曲线下面积、血液浓缩和临床充血评分均显著优于安慰剂。第15天体重减轻超过中位数与第90天临床获益概率显著更高相关(win ratio 1.75,95%CI 1.37-2.23,P<0.0001)。
要点
- 恩格列净10mg每日一次用于急性心衰住院患者,早期、有效且持续减轻充血。
- 第15、30、90天体重减轻及利尿剂调整后体重减轻均显著优于安慰剂(所有P<0.05)。
- 第15天体重减轻超过中位数与第90天临床获益概率显著更高相关(win ratio 1.75)。
核心结论
- 急性心衰住院患者启动恩格列净治疗可产生早期、有效且持续的减充血效果。
- 减充血效果与第90天临床获益相关。
研究设计与样本
- EMPULSE试验(NCT0415775)将530例急性心衰住院患者1:1随机分配至恩格列净10mg每日一次或安慰剂治疗90天。
- 评估终点包括体重减轻、利尿剂调整后体重减轻、NT-proBNP变化曲线下面积、血液浓缩和临床充血评分。
主要发现
- 恩格列净组在第15、30、90天所有减充血指标均显著优于安慰剂(所有P<0.05)。
- 第15天体重减轻调整后平均差异:-1.97(-2.86,-1.08)kg、-1.74(-2.73,-0.74)kg、-1.53(-2.75,-0.31)kg。
- 第15、30、90天利尿剂调整后体重减轻平均差异:-2.31(-3.77,-0.85)、-2.79(-5.03,-0.54)、-3.18(-6.08,-0.28)kg/40mg静脉呋塞米或等效剂量。
- 第15天体重减轻超过中位数与第90天临床获益概率显著更高相关(win ratio 1.75,95%CI 1.37-2.23,P<0.0001)。
临床怎么用
- 急性心衰住院患者可考虑早期启动恩格列净10mg每日一次以促进减充血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated. METHODS AND RESULTS: A total of 530 patients hospitalized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo for 90 days. The outcomes investigated were: weight loss (WL), WL adjusted for mean daily loop diuretic dose (WL-adjusted), area under the curve of change from baseline in N-terminal pro-B-type natriuretic peptide levels, hemoconcentration, and clinical congestion score after 15, 30, and 90 days of treatment. Compared with placebo, patients treated with empagliflozin demonstrated significantly greater reductions in all studied markers of decongestion at all time-points, adjusted mean differences (95% confidence interval) at Days 15, 30, and 90 were: for WL -1.97 (-2.86, -1.08), -1.74 (-2.73, -0.74); -1.53 (-2.75, -0.31) kg; for WL-adjusted: -2.31 (-3.77, -0.85), -2.79 (-5.03, -0.54), -3.18 (-6.08, -0.28) kg/40 mg furosemide i.v. or equivalent; respectively (all P < 0.05). Greater WL at Day 15 (i.e. above the median WL in the entire population) was associated with significantly higher probability for clinical benefit at Day 90 (hierarchical composite of all-cause death, heart failure events, and a 5-point or greater difference in Kansas City Cardiomyopathy Questionnaire total symptom score change from baseline to 90 days) with the win ratio of 1.75 (95% confidence interval 1.37, 2.23; P < 0.0001). CONCLUSION: Initiation of empagliflozin in patients hospitalized for AHF resulted in an early, effective and sustained decongestion which was associated with clinical benefit at Day 90.
引用
- Biegus, Voors, Collins, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023. PMID: 36254693. doi:10.1093/eurheartj/ehac530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。